Researcher
Marinee Chuah
- Keywords:Medicine
- Disciplines:Other basic sciences not elsewhere classified
Affiliations
- Basic (bio-) Medical Sciences (Department)
Member
From8 Apr 2019 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Division of Gene Therapy & Regenerative Medicine (Research group)
Member
From19 Apr 2011 → Today - Cell Biology and Histology (Department)
Member
From1 Oct 2010 → 31 Dec 2013 - Cell Biology and Histology (Department)
Member
From1 Oct 2010 → 30 Apr 2012
Projects
1 - 10 of 11
- SRP-Groeifinanciering: “RESTORE”: DEVELOPMENT OF INNOVATIVE GENE THERAPIES FOR GENETIC MUSCLE DISORDERSFrom1 Oct 2022 → TodayFunding: BOF - projects
- CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular DiseaseFrom1 Jan 2019 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease (OZR EU Bonus).From1 Jan 2019 → 31 Dec 2023Funding: BOF - Other initiatives
- "CURE-DMD": Development of Next-Generation Gene Therapy for Duchenne Muscular DystrophyFrom1 Jan 2017 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- Financing IOF-program GEAR: Hyperactieve Expressie-modulesFrom1 Apr 2014 → 31 Mar 2020Funding: IOF - Industrial Research Fund
- SRP (Groeiers): Next-generation gene therapy by computational vector design and immune stealth nanotechnologyFrom1 Mar 2014 → 28 Feb 2019Funding: BOF - Concerted Research Project from 1994
- In vivo genome engineering based on the CRISPR / Cas system: a new platform for functional genome analysis and gene therapyFrom1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- Development of novel "immune stealth" nanotechnology for gene therapy of hemophilia: pre-clinical validation and underlying mechanismsFrom1 Oct 2013 → 30 Jun 2014Funding: FWO fellowships
- Cardiovascular and muscle-specific "targeting" for gene therapy of neuromuscular disordersFrom1 Jan 2013 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Immune stealth nanotechnology for gene therapy of hemophilia 'A': mechanisms and translational implicationsFrom1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
Publications
21 - 30 of 64
- HEMOPHILIA GENE THERAPY(2017)
Authors: Thierry VandenDriessche, Marinee K Chuah
Pages: 1013-1023 - A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice(2017)
Authors: Simone Merlin, Elvira Stefania Cannizzo, Ester Borroni, Valentina Bruscaggin, Piercarla Schinco, Warut Tulalamba, Marinee K Chuah, Valder R Arruda, Thierry VandenDriessche, Maria Prat, et al.
Pages: 1815-1830 - AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model(2017)
Authors: Adriaan Verhelle, Nisha Nair, Inge Everaert, Wouter Van Overbeke, Lynn Supply, Olivier Zwaenepoel, Cindy Peleman, Jo Van Dorpe, Tony Lahoutte, Nick Devoogdt, et al.
Pages: 1353-1364 - Development and validation of novel computationally designed cis-regulatory modules for muscle-directed gene therapy: implications for Duchenne muscular dystrophy.(2017)
Authors: Shilpita Sarcar, Marinee K Chuah
- Next-Generation Gene Therapy for Hemophilia B using Hyperfunctional Coagulation Factor IX.(2017)
Authors: Nisha Nair, Marinee K Chuah
- Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc(-/-) mice(2016)
Authors: C. Levy, F. Fusil, F. Amirache, C. Costa, A Girard-Gagnepain, D. Negre, Ornellie Bernadin, Guillermo Garaulet, Abdel Rodriguez, N. Nair, et al.
Pages: 2478-2492 - piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts(2016)
Authors: Mariana Loperfido, Susan Jarmin, Sumitava Dastidar, Mario Di Matteo, Ilaria Perini, Marc Moore, Nisha Nair, Ermira Samara-Kuko, Takis Athanasopoulos, Francesco Saverio Tedesco, et al.
Pages: 744-760 - Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells(2015)
Authors: Sara M Maffioletti, Mattia F M Gerli, Martina Ragazzi, Sumitava Dastidar, Sara Benedetti, Mariana Loperfido, Thierry VandenDriessche, Marinee K Chuah, Francesco Saverio Tedesco
Pages: 941-958 - Genome-Wide Computational Analysis Reveals Cardiomyocyte-Specific Transcriptional CIS-Regulatory Motifs that Enable Efficient Cardiac Gene Therapy.(2015)
Authors: Melvin Rincon Acelas, Shilpita Sarcar, D. Danso-Abeam, Marleen Keyaerts, Janka Matrai, Ermira Samara, Abel Acosta-Sanchez, T. Athanasopoulos, G. Dickson, Tony Lahoutte, et al.
Pages: 43-52 - Gene therapy for cardiovascular disease(2015)
Authors: Melvin Y Rincon, Thierry VandenDriessche, Marinee K Chuah
Pages: 4-20
Patents
1 - 10 of 10
- Vectors for liver-directed gene therapy of hemophilia and methods and use thereof (Inventor)
- Muscle-specific nucleic acid regulatory elements and methods and use thereof (Inventor)
- Novel combination of nucleic acid regulatory elements and methods and uses thereof (Inventor)
- Optimized liver-specific expression systems for fviii and fix (Inventor)
- Novel combination of nucleic acid regulatory elements and methods and uses thereof (Inventor)
- Endothelium-specific nucleic acid regulatory elements and methods and use thereof (Inventor)
- Muscle-specific nucleic acid regulatory elements and methods and use thereof (Inventor)
- Vector for liver-directed gene therapy of hemophilia and methods and use thereof (Inventor)
- Cardiomyocyte-derived nucleic acid regulatory elements and methods and use thereof (Inventor)
- Vectors for liver-directed gene therapy of hemophilia and methods and use thereof (Inventor)